Dose-Dense Anthracycline Safe With Anti-HER2 Drugs

Long-term safety and efficacy results of two phase II trials indicate that dose-dense anthracycline-based chemotherapy with doxorubicin and cyclophosphamide can be safely combined with anti-HER2 therapy in women with early breast cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news